Oxford Bio to seek £30m at full listing
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Oxford Biomedica, the gene therapy company, is looking to raise £30m when it moves from the Alternative Investment Market to take a full listing early next year.
Oxford Biomedica, the gene therapy company, is looking to raise £30m when it moves from the Alternative Investment Market to take a full listing early next year.
The group said yesterday it had raised £8.5m in a share placing to fund a new gene discovery division which will adapt its gene therapy technology to identify genes actively involved in disease mechanisms. Oxford placed 14.6 million shares at 60p with institutional investors.
However, the group said that it was constrained by the market's scepticism towards biotechnology. Andrew Wood, finance director, said: "It's been an appalling time to raise money. I'd like to have got £30m in the bank, but life isn't as simple as that."
Mr Wood said Oxford BioMedica would look to raise £30m, equivalent to three years' working capital, when it takes a full listing in the first quarter of next year. The company needs to have two products in clinical trials to qualify for a full listing and so depends on its drug Trovax joining another cancer vaccine, MetXia, which is already in trials.
The company's new gene division will lift the group's cash burn from £4.5m to around £7.5m a year.
Oxford BioMedica uses discoveries from the mapping of the human genome to develop proteins that are injected into the body to stimulate genes to perform particular functions. These include genes that kill tumours and those that stop the replication of HIV, the virus that causes AIDS.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments